Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $592.69 million. The enterprise value is $90.44 million.
Important Dates
The last earnings date was Thursday, March 6, 2025, after market close.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 338.68 million shares outstanding. The number of shares has increased by 22.79% in one year.
| Current Share Class | 337.68M |
| Shares Outstanding | 338.68M |
| Shares Change (YoY) | +22.79% |
| Shares Change (QoQ) | +23.16% |
| Owned by Insiders (%) | 24.82% |
| Owned by Institutions (%) | 51.25% |
| Float | 228.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.13 |
| Forward PS | 83.40 |
| PB Ratio | 1.33 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.04, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.04 |
| Quick Ratio | 8.91 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -491.37 |
Financial Efficiency
Return on equity (ROE) is -106.27% and return on invested capital (ROIC) is -19.36%.
| Return on Equity (ROE) | -106.27% |
| Return on Assets (ROA) | -18.02% |
| Return on Invested Capital (ROIC) | -19.36% |
| Return on Capital Employed (ROCE) | -34.74% |
| Revenue Per Employee | $35,786 |
| Profits Per Employee | -$2.58M |
| Employee Count | 220 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.88% in the last 52 weeks. The beta is 1.47, so Nuvation Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -52.88% |
| 50-Day Moving Average | 2.18 |
| 200-Day Moving Average | 2.66 |
| Relative Strength Index (RSI) | 32.96 |
| Average Volume (20 Days) | 2,889,455 |
Short Selling Information
The latest short interest is 28.39 million, so 8.38% of the outstanding shares have been sold short.
| Short Interest | 28.39M |
| Short Previous Month | 26.17M |
| Short % of Shares Out | 8.38% |
| Short % of Float | 12.41% |
| Short Ratio (days to cover) | 9.84 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $7.87 million and -$567.94 million in losses. Loss per share was -$2.11.
| Revenue | 7.87M |
| Gross Profit | 795,000 |
| Operating Income | -167.56M |
| Pretax Income | -510.72M |
| Net Income | -567.94M |
| EBITDA | -166.87M |
| EBIT | -167.56M |
| Loss Per Share | -$2.11 |
Full Income StatementBalance Sheet
The company has $502.69 million in cash and $8.92 million in debt, giving a net cash position of $493.78 million or $1.46 per share.
| Cash & Cash Equivalents | 502.69M |
| Total Debt | 8.92M |
| Net Cash | 493.78M |
| Net Cash Per Share | $1.46 |
| Equity (Book Value) | 463.79M |
| Book Value Per Share | 1.37 |
| Working Capital | 468.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$130.41 million and capital expenditures -$162,000, giving a free cash flow of -$130.58 million.
| Operating Cash Flow | -130.41M |
| Capital Expenditures | -162,000 |
| Free Cash Flow | -130.58M |
| FCF Per Share | -$0.39 |
Full Cash Flow StatementMargins
| Gross Margin | 10.10% |
| Operating Margin | -2,128.25% |
| Pretax Margin | -7,213.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.79% |
| Shareholder Yield | -22.79% |
| Earnings Yield | -97.21% |
| FCF Yield | -22.35% |
Analyst Forecast
The average price target for Nuvation Bio is $8.33, which is 376.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.33 |
| Price Target Difference | 376.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 118.73% |
| EPS Growth Forecast (5Y) | -24.15% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nuvation Bio has an Altman Z-Score of 3.31 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.31 |
| Piotroski F-Score | 1 |